Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Simulations Plus Inc(SLP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SLP
09/25/2026: SLP (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Simulations Plus Inc is a specialized provider of modeling and simulation software and consulting services that assist pharmaceutical and biotech companies in optimizing drug development. The company holds a respected position in PBPK and pharmacometric modeling, benefiting from strong software margins and regulatory trust. Its main opportunity lies in the ongoing industry transition toward digital, in silico drug development. However, investors should monitor risks such as dependency on pharma R&D budgets and intense competition from larger software providers. The stock generally suits growth-oriented investors looking for exposure to the digitalization of clinical research, though they should be mindful of its mid-cap volatility.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company operates in the high-growth niche of drug discovery digitalization. |
| Momentum investor | Mixed fit | Momentum is conditional on the stock's adherence to positive breakout trends in the biotech software sector. |
| Value investor | Mixed fit | Valuation often trades at a premium due to high-margin software revenues. |
| Dividend investor | Weak fit | The dividend is modest, as the company prioritizes reinvestment for growth. |
| Low-risk investor | Weak fit | The stock exhibits volatility consistent with small-cap software and biotech-related firms. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock's small-cap status and sector exposure lead to frequent price swings. |
| Valuation risk | Medium / high | Premium multiples can contract quickly if growth expectations are not met. |
| Competition risk (Software/AI) | Medium | Stronger competitors like Certara may challenge market share in core segments. |
| Business quality | Strong | The company possesses a defensible, high-margin software business with deep customer lock-in. |
| Dividend income | Low | Income generation is not the primary objective for this growth-oriented stock. |
| Execution risk | Medium | Successful integration of acquired technologies remains critical to maintaining a technological edge. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -15.98% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 373.35M USD | Price to earnings Ratio 46.15 | 1Y Target Price 17.25 |
Price to earnings Ratio 46.15 | 1Y Target Price 17.25 | ||
Volume (30-day avg) 181.6K shares | Beta 1.33 | 52 Weeks Range 11.09 - 21.01 | Updated Date 09/27/2026 |
52 Weeks Range 11.09 - 21.01 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.4 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Software | License fees for platforms like GastroPlus and ADMET Predictor. | The core recurring revenue engine driving high margins. |
| Consulting | Professional services for drug model development and regulatory assistance. | Provides deep customer relationships that often lead to software license upgrades. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 46.15 | Forward PE 52.91 | Enterprise Value 323.04M | Price to Sales(TTM) 4.55 |
Enterprise Value 323.04M | Price to Sales(TTM) 4.55 | ||
Enterprise Value to Revenue 3.94 | Enterprise Value to EBITDA 18.87 | Shares Outstanding 20.22M | Shares Floating 16.81M |
Shares Outstanding 20.22M | Shares Floating 16.81M | ||
Percent Insiders 16.91 | Percent Institutions 79.37 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Simulations Plus Inc
Exchange NASDAQ | Headquarters Research Triangle Park, NC, United States | ||
IPO Launch date 1997-06-18 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 212 | Website https://www.simulations-plus.com |
Full time employees 212 | Website https://www.simulations-plus.com | ||
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.